| __timestamp | Geron Corporation | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 1244910 |
| Thursday, January 1, 2015 | 17793000 | 5029636 |
| Friday, January 1, 2016 | 18761000 | 4846776 |
| Sunday, January 1, 2017 | 19287000 | 5329003 |
| Monday, January 1, 2018 | 18707000 | 7121000 |
| Tuesday, January 1, 2019 | 20893000 | 9128000 |
| Wednesday, January 1, 2020 | 25678000 | 10731000 |
| Friday, January 1, 2021 | 29665000 | 10701000 |
| Saturday, January 1, 2022 | 43628000 | 16121000 |
| Sunday, January 1, 2023 | 69135000 | 37021000 |
Data in motion
In the competitive world of biotechnology, managing expenses is crucial for success. Over the past decade, Geron Corporation and Viking Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Geron Corporation's SG&A expenses surged by over 300%, peaking in 2023. This increase reflects their aggressive investment in administrative capabilities and market expansion. In contrast, Viking Therapeutics, Inc. experienced a more moderate rise, with expenses growing by approximately 290% over the same period. This suggests a more cautious approach, possibly focusing on strategic growth and cost management. The data highlights the contrasting strategies of these two companies in navigating the biotech landscape. As the industry evolves, understanding these financial trends provides valuable insights into the operational priorities and future directions of these innovative firms.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of argenx SE and Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.